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ABSTRACT: Cyclotides are head-to-tail cyclized peptides
comprising a stabilizing cystine-knot motif. To date, they are
well known for their diverse bioactivities such as anti-HIV and
immunosuppressive properties. Yet little is known about
specific molecular mechanisms, in particular the interaction of
cyclotides with cellular protein targets. Native and synthetic
cyclotide-like peptides from Momordica plants are potent and
selective inhibitors of different serine-type proteinases such as
trypsin, chymotrypsin, matriptase, and tryptase-beta. This
study describes the bioactivity-guided isolation of a cyclotide from Psychotria solitudinum as an inhibitor of another serine-type
protease, namely, the human prolyl oligopeptidase (POP). Analysis of the inhibitory potency of Psychotria extracts and
subsequent fractionation by liquid chromatography yielded the isolated peptide psysol 2 (1), which exhibited an IC50 of 25 μM.
In addition the prototypical cyclotide kalata B1 inhibited POP activity with an IC50 of 5.6 μM. The inhibitory activity appeared to
be selective for POP, since neither psysol 2 nor kalata B1 were able to inhibit the proteolytic activity of trypsin or chymotrypsin.
The enzyme POP is well known for its role in memory and learning processes, and it is currently being considered as a promising
therapeutic target for the cognitive deficits associated with several psychiatric and neurodegenerative diseases, such as
schizophrenia and Parkinson’s disease. In the context of discovery and development of POP inhibitors with beneficial ADME
properties, cyclotides may be suitable starting points considering their stability in biological fluids and possible oral bioavailability.
Natural products are considered to be a rich source fordrug discovery.1,2 In particular ribosomal synthesized and
post-translational modified peptides (RiPP) are regarded as
good starting points for pharmacological screening due to their
biological and chemical diversity. Many RiPPs contain
modifications, for instance C-terminal amidation, cyclization,
side-chain methylation or pyroglutamate formation. These
modifications are thought to be beneficial for improving ADME
properties (absorption, distribution, metabolism, and excre-
tion), such as oral bioavailability and blood-brain-barrier
passage, which are still considered as major challenges of
peptide-based drug development.3−5 The distribution of RiPPs
is widespread in nature, and they have been previously
described in isolates derived from fungi and bacteria (e.g.,
cyanobactins, thiopeptides, microcins, and lasso peptides),
plants (e.g., cyclolinopeptides and cyclotides), and animals
(e.g., scorpion toxins and conopeptides).5,6
As one representative class of RiPPs, the plant peptide family
of cyclotides are considered as potential drug lead molecules
due to their diverse bioactivities, intrinsic stability, and possible
oral bioavailability.4 Furthermore, cyclotides have been recently
described as natural templates for G protein-coupled receptor
ligand design,7 one of the most important classes of
transmembrane receptors.8 Cyclotides are expressed in many
plant species all around the world such as Violaceae, Rubiaceae,
Solanaceae, Fabaceae, and Poaceae, but their phylogenetic
distribution is still under investigation.9 The distribution of
cyclotides in the coffee-plant family (Rubiaceae) has been
extensively studied using a combined peptidomics and
transcriptomics discovery approach, and several members of
the Psychotria alliance have been identified to produce
cyclotides, i.e., Psychotria brachiata Sw., P. capitata, P. def lexa
DC., P. poeppigiana Müll. Arg., P. solitudinum Standl., and P.
suerensis Donn. Sm., as well as Carapichea ipecacuanha (Brot.)
L. Andersson, Chassalia curvif lora (Wall.) Thwaites, Notopleura
capacifolia (Dwyer) C.M. Taylor, and Palicourea tetragona
Ruiz&Pav.10 Cyclotides comprise a head-to-tail cyclized peptide
backbone and three conserved disulfide bonds, which together
form the so-called cyclic cystine-knot (CCK) motif.11 These
post-translational modifications confer them remarkable
stability in biological fluids,12 and therefore they have been
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considered as templates for peptide drug engineering.11
Utilizing the structural plasticity of the CCK framework,13
epitope grafting of bioactive peptide sequences onto the
stabilizing scaffold of cyclotides has been successfully
established and this methodology has already provided a
number of synthetic peptide drug leads.14,15 Grafted cyclotide
probes targeting the chemokine receptor CXCR4,16 the
melanocortin-4 receptor,17 the vascular endothelial growth
factor-A18 or a p53 tumor suppressor ligand19 have been
developed. Importantly, a recent study has emphasized the
potential of grafted cyclotides as oral bioactive peptide drugs,20
and hence cyclotides are gaining interest for preclinical drug
development.
Within the family of circular and cysteine-rich plant peptides
cyclotide-like peptides have been isolated from the seeds of
Momordica plants.21,22 These cyclic squash trypsin inhibitors
(TIs) share the structural CCK motif with cyclotides, but are
more similar in sequence to the acyclic squash TI peptide
family.23 On the basis of their intrinsic activity as potent
inhibitors of the serine protease trypsin and their stabilizing
CCK motif,24 Momordica-type cyclotides have been used as
templates for the design of selective proteinase inhibitors.25 For
example, development of inhibitors has been reported for the
human mast cell tryptase-beta,26 the human leukocyte
elastase,27 and the type-II transmembrane serine protease
matriptase.28,29
In summary, cyclotides including the cyclic squash TIs are
promising peptides for ligand design and drug development
due to their stability in biological fluids and their repertoire of
biological activities. Therefore, this research aims to identify
protein targets of cyclotides. The cytosolic enzyme prolyl
oligopeptidase (POP; EC 3.4.21.26), also known as prolyl
Figure 1. Analytical characterization of crude cyclotide extracts. Cyclotide extracts of plant species, i.e., Psychotria solitudinum (A), Psychotria
poeppigiana (B), Psychotria capitata (C), and Viola tricolor (D), were analyzed using MALDI-TOF MS (left panels) and RP-HPLC (right panels).
MALDI-TOF spectra are presented in the range 2500−3500 Da of each plant extract, indicating signals in a m/z range typical for cyclotides. The
molecular weights of major monoisotopic [M + H]+ signals were compared to those of known cyclotides (www.cybase.org.au or Koehbach et al.10),
identified, and labeled with names and their corresponding molecular weight. HPLC analysis was performed using linear gradients as described in the
Experimental Section, and A280 traces are presented; the gray boxes indicate HPLC fractions that have been used for POP inhibition screening (see
Supplementary Table S1).
Journal of Natural Products Article
DOI: 10.1021/np501061t
J. Nat. Prod. 2015, 78, 1073−1082
1074
endopeptidase or postproline cleaving enzyme, is a serine
protease that cleaves peptide bonds at the C-terminal side of
proline within short peptides.30 Human POP is a 81 kDa
protein and appeared to be a promising candidate as a target of
cyclotides due to the reported inhibition of different serine-type
proteases of cyclotide-like peptides isolated from Momordica
plants. Much attention is currently focused on the implication
of POP as a therapeutic target; it has been shown that
inhibitors of this protease have neuroprotective, antiamnesic,
and cognition-enhancing properties. These findings stimulated
the development of several families of POP inhibitors as
therapeutic agents for the treatment of the cognitive deficits
associated with central nervous system disorders and neuro-
degenerative diseases.31,32 In the present study a bioassay-
guided fractionation approach using three Psychotria and one
Viola plant species to identify and characterize cyclotides as a
novel class of POP inhibitors has been performed. This
approach aims to support the concept of using natural products
as a rich source of bioactive compounds for drug discovery and
in particular to exemplify that cyclotides constitute a natural
combinatorial library of circular peptides with enormous
potential for pharmacological applications.
■ RESULTS AND DISCUSSION
Prolyl oligopeptidase is known to play an important role in
many cognitive disorders such as Parkinson’s disease,33 as well
as depression and schizophrenia.34 Peptidomimetics recently
attracted attention as possible inhibitors of POP.35 Never-
theless clinical applications of peptides have been limited so far,
for instance by their low systemic stability or lack of oral
bioavailability.36 To bridge the gap of suitable peptide leads and
optimized peptide candidates for preclinical studies,32,37 the
potential of cyclotides as POP inhibitors has been investigated
in the present study.
Preparation of Plant Extracts and Analytical Charac-
terization. Plants of three Rubiaceae species, i.e., Psychotria
solitudinum, P. poeppigiana, and P. capitata, were collected in the
field in Costa Rica. The Violaceae plant Viola tricolor L. was
purchased from a commercial distributor. Plant extracts were
prepared as previously described.38 Briefly, the dried and
pulverized plant material was extracted with DCM/methanol,
and the resulting filtrate was further treated with reversed-phase
(RP) solid-phase extraction. This yielded an enriched portion
of hydrophobic compounds such as cyclotides present in those
extracts. These extracts were characterized by mass spectrom-
etry (MS) and high-performance liquid chromatography
(HPLC) (Figure 1). This peptidomics-based analytical work-
flow has been previously established10,38 and appeared to be a
rapid tool for the identification of cyclotides in the Psychotria
extracts. Molecular weight signals in the range 2500−3500 Da
that typically correspond to the presence of cyclotides were
recorded by MALDI-TOF MS in all three Psychotria extracts
(Figure 1A−C), and previously reported cyclotides psysol 1,
psypoe 1, and psycap 1 could be identified.10 Furthermore, in
agreement with an earlier study analytical HPLC analysis of
these extracts revealed late-eluting peak patterns in RP
gradients−typical for cyclotide-containing samples−indicating
the presence of cyclotides in these Psychotria extracts.10 The
prototypic cyclotide plant V. tricolor has been known as a rich
source of cyclotides, and accordingly numerous cyclotides have
been identified in the Viola extract,38,39 for example, kalata S,
varv C, varv D, varv E, varv F, vaby B, kalata B1, vigno 3,
cycloviolacin O12, and cycloviolacin O20 (Figure 1D).
Plants of the Psychotria alliance within the Rubiaceae family
offer a rich source of cyclotides.40 Indeed, Psychotria cyclotides
comprise prototypic features of the cyclotide family, which are
in particular (i) the presence of the CCK motif, which confers
them with the frequently reported stability,12 and (ii) the
sequence diversity of cyclotide loop residues, which makes
them an attractive peptide library for bioactivity screening.
Apart from cyclic Momordica TIs,23 cyclotides have to the best
of our knowledge never been characterized for their potential as
inhibitors of proteolytic enzymes. Specifically it was of interest
to study their inhibitory effects toward human POP, an enzyme
that has been identified as a promising pharmaceutical target.35
Effects of Psychotria Plant Extracts on the Activity of
Human Prolyl Oligopeptidase. Cyclotide extracts of P.
solitudinum, P. poeppigiana, P. capitata, and V. tricolor were
characterized for their effect toward the inhibitory activity of
purified human POP in a classical enzyme inhibition assay
setup similar to that described earlier by Toide and
colleagues.41 Using a high-throughput 96-well plate assay the
activity of the enzyme was determined in the presence of
different concentrations of the plant extracts. POP activity was
measured by fluorimetry using Z-Gly-Pro-AMC as substrate
following the fluorescent signal upon the enzymatic release of
AMC. The amount of fluorescence of the control samples
containing only POP enzyme and buffer was defined as 100%
activity. The activity of the corresponding cyclotide extracts was
measured and normalized to the activity of the control (eq 1,
Experimental Section). The cyclotide extracts exhibited POP
inhibition at all tested concentrations. Extracts from Psychotria
species exhibited strong inhibitory effects: at 100 μg/mL of
cyclotide extract (the lowest concentration tested), POP had a
remaining activity of 32%, 23%, and 20%, respectively, in the
presence of P. poeppigiana, P. capitata, and P. solitudinum
extract, respectively (Figure 2). Almost full inhibition was
observed when applying 400 μg/mL of cyclotide extract; that is,
the remaining POP activities were 15% for P. poeppigiana, 9%
for P. capitata, and 10% for P. solitudinum. The Viola plant
extract also exhibited POP inhibitory effects ranging from 2% to
17% remaining POP activity (Figure 2). For all extracts tested,
Figure 2. Inhibition of prolyl oligopeptidase activity by cyclotide plant
extracts. Cyclotide extracts (as shown in Figure 1) of Psychotria
solitudinum, Psychotria poeppigiana, Psychotria capitata, and Viola
tricolor were dissolved in ddH2O for the POP activity assay at
concentrations of 100−400 μg/mL and tested for their potential to
inhibit POP. The measurements were performed in triplicate, and the
data are presented as mean ± STDEV.
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the POP inhibition was concentration-dependent, and therefore
it was reasonable to assume that the observed effects were due
to a molecular interaction of POP with cyclotides of the plant
extracts.
This hypothesis is in agreement with previous observations
that squash TIs isolated from the seeds of Momordica species
inhibit the activity of other serine proteinases.21,22,29 Due to the
importance of POP in human disease42 and knowing that POP
substrates and cyclotides are similar in molecular size, we
attempted to isolate and identify cyclotides that were able to
inhibit the activity of human POP using a bioassay-guided
fractionation approach.
Bioactivity-Guided Fractionation of Cyclotide Ex-
tracts. The four cyclotide extracts that exhibited potent
inhibition of POP activity were fractionated by RP-HPLC as
previously described.38 The crude extracts, containing numer-
ous cyclotides, were separated by preparative RP-HPLC in
three to four fractions, as indicated by the gray shading in the
chromatograms of Figure 1. Those fractions were forwarded to
the POP inhibition assay and tested again in three
concentrations of 100, 200, and 400 μg/μL for each fraction
(Supplementary Table S1). All fractions of each plant extract
were capable of inhibiting the activity of POP to a certain
percentage; for example, fraction 3 of P. solitudinum (Psysol-
F3) inhibited POP activity by 48−78%, fraction 4 of P.
poeppigiana (Psypoe-F4) by 47−83%, and fraction 2 of V.
tricolor (Vitri-F2) by 51−86%, respectively. According to
MALDI-TOF MS analysis, fraction Vitri-F2 does not appear
to contain many cyclotides, but mainly other small organic
plant compounds that may be responsible for its POP
inhibitory activity (data not shown).
Three fractions of P. solitudinum were further characterized
to determine quantitative POP inhibition data (IC50) and to
purify an active cyclotide. Consequently, for all three fractions
Psysol-F1−F3 a concentration-dependent inhibition assay of
POP was performed to confirm the initial results. Psysol-F3
yielded the highest potency (IC50 = 100.4 μg/mL), whereas
fraction Psysol-F1 (IC50 = 237.2 μg/mL) and fraction Psysol-
F2 exhibited about 3-fold less potency (IC50 = 285.2 μg/mL) to
inhibit the enzymatic activity of human POP (Table 1, Figure
3A). In addition we tested POP inhibition of a subfraction of
Vitri-F3, i.e., the most potent cyclotide-containing V. tricolor
fraction. This fraction comprised a coeluting cyclotide mixture
of kalata S and kalata B1 (Supplementary Figure S1), which
exhibited a concentration-dependent inhibition of POP activity
with an IC50 of 28.5 μg/mL (Table 1, Figure 3B).
Isolation and Structural Characterization of Psysol 2
from Psychotria solitudinum. The most potent P.
solitudinum fraction, Psysol-F3, contained one major compound
(1), as determined by RP-HPLC (Figure 4A), with a molecular
weight of 2904.12 Da (Figure 4B). This peptide was purified
using semipreparative RP-HPLC, and its purity of ≥95% and its
molecular weight were confirmed by analytical RP-HPLC
(Figure 4C) and MALDI-TOF MS (Figure 4D), respectively.
To determine the peptide sequence of compound 1, which was
named psysol 2 (Psychotria solitudinum cyclotide 2), a
previously optimized MALDI-based peptidomics approach
has been utilized.43 Initially the cysteine content of the peptide
was determined by a combination of reduction and alkylation.
Purified psysol 2 (1) was treated with dithiothreitol (DTT),
and the reduced sulfhydryl groups were modified with
iodoacetamide. This chemical derivatization resulted in an
addition of 348.1 Da, which corresponds to the presence of six
cysteine residues (Figure 5A,B). Subsequently the reduced and
S-alkylated aliquots of psysol 2 (1) were digested with trypsin
or endoproteinase GluC to confirm the presence of a circular
backbone and to elucidate the peptide’s primary sequence by de
novo peptide sequencing. Upon trypsin and endoproteinase
GluC digest of the sulfhydryl-reduced and S-alkylated peptide,
its molecular weight increased by 18 Da as a result of the
addition of H2O during “ring-opening” of the backbone-
cyclized peptide (Figure 5C,D); this confirmed the cyclic
nature of psysol 2 (1), and it indicated the presence of one Lys
or Arg residue and one Glu residue in the peptides’ sequence,
respectively. Manual interpretation of the MS/MS peptide
fragmentation pattern of each digest revealed the sequence of
psysol 2 (1) (Figure 5C,D). Since the two isobaric residues Leu
and Ile cannot be resolved by MS/MS fragmentation,
homology alignment analysis10 (www.cybase.org.au) of psysol
2 (1) to other known cyclotides, in particular to closely related
Psychotria cyclotides, has been performed; hence this combined
approach led to the identification of the psysol 2 (1) sequence
as cyclo-GLPICGESCVGGTCNTPGCTCTWPVCTRN (Fig-
ure 6A).
Since psysol 2 (1) contains six cysteine residues and a
circular peptide backbone, it is likely to form the typical CCK
motif.10 The presence of a Pro residue in loop 5 allowed
classification of psysol 2 (1) as a Möbius-type cyclotide due to
sequence homology to other cyclotides of this subfamily
(Figure 6 A).11 In addition to the similar molecular sequence of
psysol 2 (1) and known cyclotides, the structural similarity has
been confirmed by modeling of psysol 2 (1) using the
CycloMod tool of CyBase44 (Figure 6B). The sequence
alignment of prototypic cyclotides with psysol 2 (1), namely,
kalata B1 (Möbius), cycloviolacin O2 (bracelet), and MCoTI-1
(cyclic TI) clearly demonstrated that psysol 2 (1) has the
highest homology with kalata B1, with only three residues
differing, in positions 4, 7, and 22. Compared to cycloviolacin
O2, psysol 2 (1) lacks the cationic residues in loop 5 and the
hydrophobic residue in loop 3. As mentioned above, the
Momordica TIs and cyclotides share only the CCK motif,45 and
hence psysol 2 (1) and MCoTI-1 have little sequence
homology. The psysol 2 (1) model further predicted a triple-
stranded β-sheet as a secondary structure element, which is
typical for Möbius-type cyclotides.
Structure−Activity and Specificity of Cyclotide POP
Inhibitors. Plant purified psysol 2 (1) was tested for POP
inhibitory activity, and as expected from bioassay-guided
fractionation, it inhibited human POP activity with an IC50 of
Table 1. POP Enzyme Inhibition Potency of Cyclotides
fraction/compound IC50 [μg/mL]
Psysol-F1 237.2 ± 23.4a
Psysol-F2 285.2 ± 58.9a
pPsysol-F3 104.3 ± 16.0a
Vitri-F3 (subfraction) 28.5 ± 0.3a
IC50 [μM]
psysol 2 (1) 25.0 ± 0.3;a (27.8b,c)
kalata B1 5.6c
aIC50 values are calculated using nonlinear regression analysis and are
presented as mean ± STDEV of at least two independent experiments
(as described in the Experimental Section). bPotency of synthetic
cyclotide is shown in parentheses. cValues are presented as the mean
of three replicates.
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Figure 3. Concentration-dependent inhibition of human prolyl oligopeptidase by cyclotides. (A) Concentration-response inhibition curves of three
Psychotria solitudinum fractions (Psysol-F1−F3) after RP-HPLC fractionation of the cyclotide extract. Each data point is presented as the mean ±
STDEV of two independent experiments or as the mean of three replicates, respectively (see Table 1). The inhibitory potency was quantified using
nonlinear regression analysis, yielding IC50 values of 237.2 μg/mL (Psysol-F1), 285.2 μg/mL (Psysol-F2), and 100.4 μg/mL (Psysol-F3). Similarly,
Viola tricolor fraction (Vitri-F3) was purified by RP-HPLC to yield sample sub-Vitri-F3. This subfraction comprises mainly the two coeluting
cyclotides kalata S and kalata B1 (Supplementary Figure S1). (B) The fraction exhibited a POP inhibitory potency (IC50) of 28.5 μg/mL. The most
potent fraction of Psychotria solitudinum (Psysol-F3) was further purified to obtain the isolated cyclotide psysol 2 (1), which inhibited human POP
activity in a concentration-dependent manner with an IC50 of 25 μM (C, solid line). To confirm the inhibition of human POP by plant-extracted
cyclotides, psysol 2 (1) and kalata B1 were synthesized and analyzed; synthetic psysol 2 (1) (C, dashed line) inhibits human POP activity in a
concentration-dependent manner with an IC50 of 27.8 μM, and synthetic kalata B1 yielded an IC50 of 5.6 μM (D).
Figure 4. Purification and analysis of psysol 2 (1). The analytical A280 HPLC trace of Psychotria solitudinum fraction 3 (Psysol-F3) (A) and its
corresponding MALDI-TOF spectrum (B) are shown, indicating the presence of one main compound in this fraction. Using RP-HPLC separation a
single compound, 1, could be isolated from this fraction. This purified compound 1 was characterized by RP-HPLC (C) and MALDI-TOF MS (D).
Inset in (D) shows the isotope pattern of psysol 2 (1). HPLC indicated a purity of >95%.
Journal of Natural Products Article
DOI: 10.1021/np501061t
J. Nat. Prod. 2015, 78, 1073−1082
1077
25 ± 0.3 μM. The activity was confirmed with a synthetic
psysol 2 cyclotide (Supplementary Figure S2), which exhibited
an IC50 of 27.8 μM (Table 1, Figure 3C). Since psysol 2 (1)
and kalata B1 share high sequence homology and knowing that
the active V. tricolor fraction Vitri-F3 contains kalata B1, we
synthesized this cyclotide (Supplementary Figure S2) and
analyzed its POP inhibitory activity. Kalata B1 was slightly
more potent and inhibited human POP activity with an IC50 of
5.6 μM (Table 1, Figure 3D). These observed differences in
activity may be due to the amino acid differences and/or minor
structural variation between the two cyclotides.
Similar plant peptides, namely, the family of cyclic and acyclic
squash TI peptides, are well-known inhibitors of trypsin and
chymotrypsin. To determine inhibitor specificity of cyclotides,
we therefore tested the ability of kalata B1 and psysol 2 (1) to
inhibit the activity of those two pancreatic enzymes
(Supplementary Figure S3). Interestingly, cyclotides were not
capable of inhibiting the activity of trypsin or chymotrypsin at
concentrations of 25 and 75 μM, respectively. This suggests
that cyclotides, and in particular kalata B1, are at least an order
of magnitude more selective toward inhibition of POP over
trypsin and chymotrypsin.
It is noteworthy that psysol 2 (1) and kalata B1 contain three
proline residues each (Figure 6), and prolyl groups are thought
to be a key feature of many POP substrates.42 This is also the
case for other active cyclotides that have been identified in the
POP inhibitory fractions of the other plant extracts (Figure 1);
most of them contain three proline residues, in loops 3, 5, and
6, respectively (Supplementary Figure S4). It will be interesting
in future studies to determine the importance of those Pro
residues for the inhibitory activity of cyclotides. In summary the
observed bioactive properties and structural features of
cyclotides warrant further investigations for applications of
these interesting circular peptides as human POP inhibitors.
Drug Development Potential of Cyclotide-Based POP
Inhibitors. The vast majority of previously known POP
inhibitors are small-molecule peptidomimetics based on
systemic modifications of the canonical compound benzylox-
Figure 5. De novo sequencing of the cyclotide psysol 2 (1). The isolated active compound 1 of Psychotria solitudinum was characterized by chemical
derivatization and MS. Using sulfhydryl reduction by DTT a mass shift of 6 Da (2911.12 m/z) compared to the native mass signal of 2905.12 m/z
was observed, indicating the presence of six cysteine residues (A). Subsequently, iodoacetamide derivatization yielded the mass of 3253.22 m/z,
corresponding to S-carbamidomethylation of the six cysteines (B). De novo amino acid sequencing was performed by interpretation of MS/MS
fragmentation spectra using trypsin (C) and endoproteinase Glu C (D) digests. The sequence was determined by manual assignment of the N-
terminal b-ion and C-terminal y-ion series and the ion fragmentation calculator tool (Data Explorer AB Sciex). The disulfide connectivity of Cys I−
IV, Cys II−V, and Cys III−VI and the isobaric amino acids Leu and Ile were assigned based on homology with known sequences.10
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ycarbonyl-prolyl-prolinal (Z-Pro-prolinal). This compound acts
as a transition-state analogue due to the presence of a covalent
group acting as a “warhead”.31,32 Although many peptidomi-
metics, for example, S-17092, Z-321, JTP-4819, and ONO-
1603, have been described as POP inhibitors with micromolar
to nanomolar potencies, the presence of a warhead moiety is an
important parameter to obtain inhibitory potencies in the low
nanomolar range.31,32 Despite some initial success as potential
therapeutics of cognitive deficits associated with aging and
Alzheimer’s disease, the development of these peptidomimetics
was discontinued during clinical phase I and II, respectively.35
Due to a lack of public information, it is not clear why these
compounds failed, but most known POP inhibitors comprise
the narrow family of pyrrolidinyl analogues.35 To our
knowledge there are currently no “classical peptide” POP
inhibitors available. It has been repeatedly highlighted that
cyclotides are an emerging peptide class with enormous
potential in medicinal chemistry and for pharmaceutical
applications.4,7,12,14,15,20 Therefore, cyclotides may be promis-
ing tools for the development of novel peptide-based POP
inhibitor drugs.
The most interesting features of cyclotides are their circular
peptide backbone and the cystine-knot fold constituting the
CCK motif. Together this improves the stability of these
peptides, and hence cyclotides are known to be heat-stable,
resistant to proteolytic degradation, and unaffected by the
acidic pH conditions in the gastrointestinal tract,12 all of which
are prerequisites for conferring peptides with oral bioavail-
ability.20 Another feature of cyclotides is their enormous
diversity and sequence variation. It has been well documented
that the majority of the amino acids within the intercysteine
loops are amenable to variation without affecting CCK
topology,13 and indeed hundreds of cyclotides displaying
unique amino acid sequences have been isolated from plants.46
This natural variation together with the structural plasticity of
cyclotides has been recognized by peptide chemists to engineer
novel cyclotide-based peptide therapeutics,12,16−19,26−29 by
grafting of linear and otherwise unstable bioactive amino acid
sequences onto the intercysteine loops of cyclotides to
“protect” them from degradation within the stabilized CCK
framework.15
Although peptide grafting is a promising tool in drug
development,47 there are examples of naturally occurring cyclic
or disulfide-knotted peptides, which appeared to be potent
protease inhibitors. For example a cyclic peptide stabilized by
one disulfide bond is the sunflower-trypsin inhibitor SFTI-1,
which inhibits serine proteases. SFTI-1 is considered to be the
smallest known peptide trypsin inhibitor (14-mer) and belongs
to the Bowman-Birk inhibitor family. As mentioned above,
squash TIs are also potent inhibitors of trypsin and
chymotrypsin,48 and this includes in particular the cyclotide-
like cyclic squash TIs isolated from Momordica plants.21 The
present study has confirmed these previous examples that cyclic
or disulfide-knotted peptides, and in particular cyclotides, are
naturally occurring inhibitors of serine proteases. In addition,
we were able to demonstrate that Möbius-type cyclotides do
not inhibit the enzymatic activity of trypsin and chymotrypsin,
but appear to be specific for inhibition of prolyl-oligopeptidase.
The combination of having a natural peptide template with
intrinsic inhibitory potency against proteases and knowing that
the CCK-fold is amenable to peptide engineering for
optimization of this given activity makes the family of cyclotides
interesting natural molecules for future investigations regarding
design and development of human POP inhibitors.
To conclude, the present study described the identification of
the cyclotides kalata B1 and psysol 2 (1) to inhibit human POP
activity in vitro. This may have provided lead compounds for
further investigation in the field of POP therapeutics. There are
currently no POP inhibitors available as approved drugs, and
consequently there is a need for discovery and development of
suitable and improved POP inhibitors. Cyclotides can be
regarded as the first of a novel class of circular peptide POP
inhibitors. Due to their known potential in peptide drug
development,4,7,12,14,15,20 cyclotides appear to be an interesting
class of natural products for future studies to design and
develop human POP inhibitors.
■ EXPERIMENTAL SECTION
General Experimental Methods. RP-HPLC was performed
using a Dionex Ultimate 3000 station (Dionex, Amsterdam, The
Netherlands).38,49 The device was equipped with a binary pump,
autosampler, column oven, multiwavelength detector, and fraction
collector. Absorbance wavelengths of 214, 254, and 280 nm were
recorded of all analytical and preparative separations.
Plant Material. Psychotria plant material (Psychotria solitudinum, P.
capitata, and P. poeppigiana) was collected in Costa Rica at the tropical
research station La Gamba, and species were identified by H. Greger
and A. Berger (University of Vienna, Austria).10 Herbarium accession
numbers are HG-2607083, HG-24070811, and HG-3007081,
respectively. Collection and export of plant material were kindly
permitted by the Costa Rican Ministry of Ambient and Energy under
permit numbers 050-2013-SWAC, 217-2012-SWAC, and DGVS-109-
2013, respectively. Samples were dried, stored at 23 °C, and protected
from moisture and UV irradiation until extraction. Pulverized Viola
tricolor L. (Violaceae) plant material (Herba Violae Tricoloris plv.) was
purchased from Kottas Pharma GmbH (Vienna, Austria).
Extraction and Isolation. Cyclotide extracts were prepared as
previously described.38 Briefly, dry plant material was ground using a
coffee grinder and extracted for 24 h in 100−200 mL of
dichloromethane/methanol, 1:1 (v/v), by continuous agitation at 23
°C. After filtration, 0.5 vol of ddH2O was added, and the methanol/
water phase, which contained the enriched cyclotide mixture, was
obtained by liquid/liquid phase separation. This aqueous extract was
treated with RP C18 solid-phase extraction. First, the methanol content
was reduced to less than 10% vol by dilution with ddH2O. Solid-phase
extraction was performed using ZEOprep 60 Å, C18 irregular 40−63
μm material (Zeochem, Uetikon, Switzerland) that has been activated
Figure 6. Sequence alignments and homology model of psysol 2 (1).
(A) The amino acid sequence of psysol 2 (1) was used for alignment
based on the conserved CCK motif with the prototypic cyclotides
kalata B1 (Möbius type), cycloviolacin O2 (bracelet), and MCoTI-1
(cyclic TI). The structural model of the novel cyclotide psysol 2 (1)
was obtained with the CycloMod tool (www.cybase.org), and the
structural features were compared to kalata B1 (pdb code: 1NB1),
cycloviolacin O2 (2KNM), and MCoTI-1 (1IB9). All structures are
presented as ribbon cartoons, which were prepared using PyMol. β-
sheet motifs are indicated by flat arrows, and the disulfide bonds are
highlighted in yellow.
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with methanol and equilibrated using 0.1% trifluoroacetic acid (TFA).
The aqueous extract was applied to the C18 material, washed with
ddH2O/CH3CN/TFA, 90/10/0.1% (v/v/v), and eluted with ddH2O/
CH3CN/TFA, 20/80/0.1% (v/v/v). These eluates were lyophilized
and reconstituted in ddH2O buffer prior to the POP inhibition tests or
in 0.1% TFA for mass spectrometry based analysis or HPLC
separation.
Further cyclotide purification was achieved by preparative
chromatography with a Phenomenex Jupiter C18 column (250 ×
20.2 mm, 10 μm), and semipreparative separation was carried out with
a Dichrom Kromasil C18 column (250 × 10 mm, 5 μm). Flow rates
were set to 8 and 3 mL/min, respectively, and the solvents consisted of
0.1% TFA (solvent A) or ddH2O/CH3CN/TFA, 10/90/0.1% (v/v/v)
(solvent B). Linear gradients from 5% to 65% solvent B (1% per min)
were applied to achieve separation of extracts. Resulting fractions were
freeze-dried and analyzed by analytical HPLC using a Phenomenex
Kinetex (150 × 3 mm, 2.1 μm) column. Purified cyclotide psysol 2 (1)
was further structurally characterized by de novo peptide sequencing
using MALDI-TOF/TOF and homology modeling using CyBase
tools.
Peptide Sequencing. Cyclotide structural elucidation of the
cyclotide psysol 2 (1) was performed by MS using a MALDI-TOF/
TOF 4800 analyzer from AB Sciex (Framingham, MA, USA) as
previously described.10 Peptide mapping of plant extracts or HPLC
fractions was performed by dissolving dried sample material in 0.1%
TFA. The samples were mixed at a ratio of 1:6 (v/v) with a matrix
solution consisting of saturated α-cyano-4-hydroxycinnamic acid
(Sigma-Aldrich, St. Louis, MO, USA) in ddH2O/CH3CN/TFA, 50/
50/0.1% (v/v/v). A 0.5 μL aliquot of the mixture was directly spotted
onto the MALDI target plate, and the droplet was allowed to air-dry.
Mass spectra were obtained by combining 2500 shots in the spectral
range 2500 to 4500 m/z using the MS reflector positive ionization
mode. For de novo sequencing peptides were dissolved at a
concentration of 5 mg/mL in 0.1 M NH4HCO3 (pH 8.0), and
disulfide bonds were reduced using DTT in a final concentration of 10
mM for 60 min at 37 °C. The sample was S-alkylated using
iodoacetamide (100 mM) for 10 min in the dark; remaining alkylation
reagent was quenched by addition of DTT (5 mM). Prior to MS/MS
fragmentation the peptide was digested with 0.2 μg of trypsin
“proteomics grade” (Sigma-Aldrich) or 0.4 μg of endoproteinase GluC
“proteomics grade” (New England Biolabs, Ipswich, MA, USA). The
digest was performed at 37 °C for 16−18 h, and the peptide mixture
was quenched using 0.5% TFA followed by ZipTip desalting
(Millipore, Billerica, MA, USA). Precursor fragmentation was obtained
in the MS/MS positive 1 kV reflector mode by acquiring
approximately 5000 spectra using optimized laser intensity and
digitizer enhancement settings. All MS/MS spectra were recorded
using the metastable ion suppressor function. The cyclotide amino
acid sequence was obtained by manual assignment of N-terminal b-ion
and C-terminal y-ion series and automated sequence analysis using the
DataExplorer software (AB Sciex). The disulfide connectivity of CysI-
IV, CysII-V, and CysIII-VI and the isobaric amino acids Leu and Ile
were assigned based on homology with known sequences.10
Cyclotide Homology Modeling. The three-dimensional struc-
ture of the cyclotide psysol 2 (1) was performed by homology
modeling using the CycloMod tool on CyBase (www.cybase.org.au).
Structural images were prepared using PyMol from the pdb files for
kalata B1 (1NB1), cycloviolacin O2 (2KNM), and MCoTI-1 (1IB9).10
Cyclotide Synthesis. The cyclotides psysol 2 (1) and kalata B1
have been synthesized by Fmoc-based solid-phase peptide synthesis,
folded, and analyzed using previously established protocols.7,50
Prolyl Oligopeptidase Inhibition Assays. Samples were
prepared by dissolving freeze-dried material in ddH2O buffer. Several
concentrations of cyclotide extracts or fractions between 100 and 400
μg/μL were used for the measurement. The purity of isolated or
synthesized psysol 2 (1) and kalata B1 was evaluated with RP-HPLC
at A280, and their concentrations were determined using the Beer−
Lambert law with the molar absorption coefficients of 5875 cm−1 M−1
(psysol 2) and 6410 cm−1 M−1 (kalata B1), respectively. For the POP
inhibition assay the reactions were performed in triplicate in 96-well
microtiter plates. Human POP (2 μL of a 6 μM solution; prepared by
recombinant expression according to Tarrago et al.51) was
preincubated for 15 min at 30 °C with buffer (137 μL of a 0.1 M
Na2HPO4 and KH2PO4 (1:1, w/w) solution, pH 7.4) and the
corresponding cyclotide extract solution (3 μL) or ddH2O (3 μL,
controls). After preincubation, POP substrate (Z-Gly-Pro-AMC, 10 μL
of a 3 mM solution prepared in 40% 1,4-dioxane; Bachem, Bubendorf,
Switzeland) was added, and the reaction mixture was incubated while
shaking (90 rpm) for 1 h at 37 °C. The formation of AMC was
measured by fluorimetry. The excitation and emission wavelengths
were 360 ± 40 and 485 ± 20 nm, respectively. The percentage of
inhibition was calculated as
− ×X Y X[( )/ ] 100 (1)
where X is the activity of POP in the absence of the inhibitor and Y is
the activity in the presence of the cyclotide solution. The IC50 value
was defined as the concentration of compound required to inhibit 50%
of POP activity under these assay conditions. The inhibition data were
analyzed using GraphPad Prism5 v 5.04. Inhibition curves were
generated by plotting the logarithmic concentrations vs enzyme
activity, and IC50 values were calculated by fitting the data to a three-
parameter Hill equation using nonlinear regression analysis. Each
inhibitory experiment was repeated independently twice, unless
otherwise stated, and IC50 values were calculated from each biological
repeat and are presented as mean ± STDEV.
Trypsin and Chymotrypsin Inhibition Assays. Inhibitory
activity was performed in triplicate in 96-well microtiter plates. Bovine
trypsin (10 μL of a 10 ng/μL solution; Roche, Basel, Switzerland) or
bovine α-chymotrypsin (10 μL of a 2.5 ng/μL solution; Sigma-
Aldrich) was preincubated for 15 min at 37 °C with buffer (125 μL of
a 20 mM Tris-HCl solution, pH 8.0) and with 3 μL of the cyclotide
solution or ddH2O as negative control. After preincubation, trypsin
substrate (Bz-Arg-AMC-HCl, 10 μL of a 3 mM solution prepared in
40% 1,4-dioxane; Bachem, Bubendorf, Switzerland) or chymotrypsin
substrate (Ala-Ala-Phe-AMC, 10 μL of a 3 mM solution prepared in
40% 1,4-dioxane; Sigma-Aldrich), respectively, was added, and the
reaction was incubated while shaking (90 rpm) for 1 h at 37 °C. The
reaction was stopped with sodium acetate (150 μL, 1 M, pH 4), and
the formation of AMC was measured by fluorimetry. The excitation
and emission wavelengths were 360 ± 40 and 485 ± 20 nm,
respectively. Phenylmethane-sulfonylfluoride (PMSF; 3 μL of a 5 mM
solution in DMSO) was used as a positive control of inhibition;
additional controls with DMSO solution only were also performed.
Data were calculated as percentage of inhibition and are presented as
mean ± STDEV (of three replicates).
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